NCT04673786View on ClinicalTrials.gov

A Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients With Plaque Psoriasis

PHASE3CompletedINTERVENTIONAL
Enrollment

509

Participants

Timeline

Start Date

January 11, 2021

Primary Completion Date

August 4, 2021

Study Completion Date

May 12, 2022

Conditions
Psoriasis
Interventions
BIOLOGICAL

CT-P43

45mg or 90mg dose subcutaneous administration

BIOLOGICAL

Stelara

45mg or 90mg dose subcutaneous administration

Trial Locations (1)

50106

Clinical Research Centre, Tartu

Sponsors

Lead Sponsor

Celltrion
All Listed Sponsors
lead

Celltrion

INDUSTRY

NCT04673786 - A Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients With Plaque Psoriasis | Biotech Hunter | Biotech Hunter